Integrum's OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
MÖLNDAL,
The clinical study will be important for the future approval of the OPRA™ Implant System on the below-knee amputation level, which is the most frequent amputation level. The study will be performed by the Walter Reed National Military Medical Center.
"This is an important milestone in the expansion of indications for our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.
For more information please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser.
The following files are available for download:
https://mb.cision.com/Public/17531/3865375/ae332572d5827e27.pdf | 2023-10-30 Integrum PR IDE TTA |
View original content:https://www.prnewswire.com/news-releases/integrums-opra-implant-system-gets-fda-approval-for-clinical-study-on-below-knee-amputations-301971151.html
SOURCE Integrum AB